Literature DB >> 20820874

Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy.

Maximilian I Ruge1, Josef Ilmberger, Jörg-Christian Tonn, Friedrich-Wilhelm Kreth.   

Abstract

The present prospective study intends to evaluate health-related quality of life (HRQL) and cognitive functioning in adult patients with supratentorial World Health Organization (WHO) grade II glioma (LGG) prior to observation/therapy and to determine possible influences of tumor-related factors on these measures. Adult patients with biopsy-proven supratentorial LGG were considered eligible (study period 18 months). Besides detailed documentation of patient clinical status we evaluated HRQL using the Short Form-36 (SF-36) Health Survey and applied the Beck Depression Inventory. Furthermore, attention and verbal memory functions were tested. Data from matched healthy control populations served as reference, and T-values were compared using Mann-Whitney U tests. For correlation of scores the Pearson test was utilized. Thirty-three patients with median Karnofsky Performance Status (KPS) of 80 were evaluated. Selective and divided attention showed significant impairment (P < 0.005), while verbal memory functions were unaffected. HRQL evaluated by SF-36 Health Survey was significantly reduced predominantly in the psychological domains (P < 0.025 to P < 0.0005). Nine patients displayed mild to moderate depression. Duration of symptoms >20 weeks and presence of seizures negatively affected aspects of HRQL, while cognitive functions were not influenced. KPS <80 correlated significant only with reduced physical functioning (P < 0.002) and role functioning (P < 0.01) on the SF-36 Health Survey. While displaying good clinical status, patients with LGG showed significant impairment in aspects of attention and affections of HRQL already at time of diagnosis. These results suggest that these impairments originate from the tumor and/or potentially from confrontation with the diagnosis itself.

Entities:  

Mesh:

Year:  2010        PMID: 20820874     DOI: 10.1007/s11060-010-0364-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Assessment of quality of life in patients treated for low-grade glioma: a preliminary report.

Authors:  M J Taphoorn; J J Heimans; F J Snoek; J Lindeboom; B Oosterink; J G Wolbers; A B Karim
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

Review 2.  Current concepts in the evaluation and management of WHO grade II gliomas.

Authors:  Joseph M Piepmeier
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

3.  Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas.

Authors:  J C Reijneveld; M M Sitskoorn; M Klein; J Nuyen; M J Taphoorn
Journal:  Neurology       Date:  2001-03-13       Impact factor: 9.910

4.  Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy.

Authors:  M J Taphoorn; A K Schiphorst; F J Snoek; J Lindeboom; J G Wolbers; A B Karim; P C Huijgens; J J Heimans
Journal:  Ann Neurol       Date:  1994-07       Impact factor: 10.422

5.  Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study.

Authors:  M Klein; J J Heimans; N K Aaronson; H M van der Ploeg; J Grit; M Muller; T J Postma; J J Mooij; R H Boerman; G N Beute; G J Ossenkoppele; G W van Imhoff; A W Dekker; J Jolles; B J Slotman; H Struikmans; M J B Taphoorn
Journal:  Lancet       Date:  2002-11-02       Impact factor: 79.321

6.  Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.

Authors:  G M Kiebert; D Curran; N K Aaronson; M Bolla; J Menten; E H Rutten; E Nordman; M E Silvestre; M Pierart; A B Karim
Journal:  Eur J Cancer       Date:  1998-11       Impact factor: 9.162

7.  Longitudinal cognitive follow-up in low grade gliomas.

Authors:  Denise D Correa; Weiji Shi; Howard T Thaler; Angeles M Cheung; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Neurooncol       Date:  2007-10-10       Impact factor: 4.130

8.  Treatment and survival of low-grade astrocytoma in adults--1977-1988.

Authors:  B M McCormack; D C Miller; G N Budzilovich; G J Voorhees; J Ransohoff
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

9.  Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial.

Authors:  Karin Gehring; Margriet M Sitskoorn; Chad M Gundy; Sietske A M Sikkes; Martin Klein; Tjeerd J Postma; Martin J van den Bent; Guus N Beute; Roelien H Enting; Arnoud C Kappelle; Willem Boogerd; Theo Veninga; Albert Twijnstra; Dolf H Boerman; Martin J B Taphoorn; Neil K Aaronson
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

10.  Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life.

Authors:  Martin Klein; Nadine H J Engelberts; Henk M van der Ploeg; Dorotheé G A Kasteleijn-Nolst Trenité; Neil K Aaronson; Martin J B Taphoorn; Hans Baaijen; W Peter Vandertop; Martin Muller; Tjeerd J Postma; Jan J Heimans
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

View more
  13 in total

1.  Cognitive functioning in newly presenting patients with supratentorial intracranial tumors: is there a role for inspection time?

Authors:  Jennifer L Scotland; Ian R Whittle; Ian J Deary
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

Review 2.  The need to consider return to work as a main outcome in patients undergoing surgery for diffuse low-grade glioma: a systematic review.

Authors:  Juan Silvestre G Pascual; Hugues Duffau
Journal:  Acta Neurochir (Wien)       Date:  2022-08-09       Impact factor: 2.816

Review 3.  Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.

Authors:  Martin Klein
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 4.  Factors influencing quality of life in adult patients with primary brain tumors.

Authors:  Rakesh Jalali; Debnarayan Dutta
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 5.  Reporting of patient-reported health-related quality of life in adults with diffuse low-grade glioma: a systematic review.

Authors:  Daniel M Fountain; Dominic Allen; Alexis J Joannides; Dipankar Nandi; Thomas Santarius; Aswin Chari
Journal:  Neuro Oncol       Date:  2016-05-18       Impact factor: 12.300

6.  Seizures in patients with primary brain tumors: what is their psychosocial impact?

Authors:  John Y Shin; Sani H Kizilbash; Steven I Robinson; Joon H Uhm; Julie E Hammack; Daniel H Lachance; Jan C Buckner; Aminah Jatoi
Journal:  J Neurooncol       Date:  2016-03-15       Impact factor: 4.130

Review 7.  Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.

Authors:  Linda Dirven; Jacob C Reijneveld; Neil K Aaronson; Andrew Bottomley; Bernard M J Uitdehaag; Martin J B Taphoorn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

8.  Neurocognitive functioning and health-related quality of life in patients with radiologically suspected meningiomas.

Authors:  D van Nieuwenhuizen; N Ambachtsheer; J J Heimans; J C Reijneveld; S M Peerdeman; M Klein
Journal:  J Neurooncol       Date:  2013-05-03       Impact factor: 4.130

9.  Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Thorsten Simon; Harald Treuer; Volker Sturm
Journal:  J Neurooncol       Date:  2012-05-12       Impact factor: 4.130

10.  Quality of life measures as a preliminary clinical indicator in patients with primary brain tumors.

Authors:  Lisa B E Shields; Aliisha Choucair; Ali K Choucair
Journal:  Surg Neurol Int       Date:  2013-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.